Paraganglioma Mimicking a Pancreatic Neoplasm

Nicole Lightfoot1, Peter Santos2, Mehrdad Nikfarjam3

Departments of 1Pathology, 2Nuclear Medicine, and 3Surgery; University of Melbourne, Austin Health. Heidelberg, VIC, Australia

ABSTRACT

Context Paragangliomas are rare tumours of neural crest origin. Extra-adrenal pancreatic paragangliomas are exceptionally rare.

Case report A 66-year-old man with abdominal pain was noted to have a complex pancreatic head and uncinate process mass on imaging. He underwent complete resection by pancreaticoduodenectomy with final pathology confirming a 6 cm paraganglioma without evidence of metastases. On histology the tumour was arising from the retroperitoneum and abutting the pancreas. The patient was disease free at 14-month follow-up. Conclusion Pancreatic paragangliomas represent in many cases the retroperitoneal extension of a paraganglioma into the pancreas rather than a true pancreatic neoplasm. Although generally benign, the risk of malignant transformation justifies aggressive management.

INTRODUCTION

Extra-adrenal paragangliomas are tumours of the autonomic nervous system which arise from the neural crest. Common sites include the head and neck region, mediastinum and retroperitoneum. Paragangliomas also infrequently occur within organs, arising from paraganglia, which are collections of neuroepithelial cells [1]. Paraganglioma arising within the pancreas is rare. It is equivocal whether reported cases truly arise within pancreatic parenchyma, or represent extension from extra-pancreatic sites. We report the case of a pancreatic paraganglioma and discuss the features associated with this tumour.

CASE REPORT

A 66-year-old man who presented with sudden onset abdominal pain, found on computed tomography (CT) to have a complex solid and cystic mass involving the head and uncinate process of the pancreas, measuring 6 cm (Figure 1). Positron emission tomography (PET) showed mild metabolic activity adjacent to the cystic component but was non-diagnostic for malignancy. Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) were not elevated. Chromogranin A was mildly elevated at 78 U/L (reference range: 0-21.8 U/L). Pancreaticoduodenectomy was required to achieve complete tumour excision. The tumour was well circumscribed and located adjacent to the coeliac and superior mesenteric artery, abutting the pancreas. The tumour could not be separated from pancreatic tissue and had extensive intra-tumoural haemorrhage. Histology revealed a tumour composed of spindled to polygonal cells with abundant basophilic granular cytoplasm and moderate pleomorphism. The cell architecture was trabecular and nested, pathognomonic of paraganglioma (Figure 2a). The tumour had a prominent sinusoidal capillary network with widespread haemosiderin deposition, consistent with previous haemorrhage. Low mitotic activity was observed and there was no capsular invasion. The tumour was encapsulated and demarcated from the surrounding effaced pancreatic parenchyma (Figure 2b). Tumour cells stained positively for synaptophysin, chromogranin and S100 (Figure 3). The morphological and immunohistochemical profile was consistent with extra-adrenal paraganglioma.

The patient’s post-operative course was unremarkable. There was no evidence of disease recurrence at 14 months post operatively. Genetic testing for the succinate dehydrogenase subunit D (SDHD) and Von Hippel-Lindau (VHL) mutations, which are commonly associated with inherited and sporadic paragangliomas, were normal.

DISCUSSION

Extra-adrenal paraganglioma arising within the pancreas is an extremely rare entity with only 15 cases reported in the literature [2, 3, 4, 5]. The retro-
peritoneum is the more typical location and it is equivocal whether paraganglioma of the pancreas represents extension from a retroperitoneal tumour or true visceral origin with derivation from ectopic paraganglia [4, 5]. In our case, the neoplasm was involving the pancreatic head radiologically; however, was encapsulated and demarcated from the surrounding effaced parenchyma.
Paragangliomas are reported at multiple locations throughout the pancreas, including the head, body and tail [1, 5]. Pancreatic paragangliomas are generally non-functional [1]. This contrasts with other sites, where functional activity is more common, with catecholamine secretion reported in 30-60% of tumours associated with symptomatic hypertension, headache, palpitations and sweating [4]. Non-secretory tumours may present with abdominal pain or palpable mass or represent incidental radiological findings [1, 4]. Radiologically, paragangliomas show a homogeneous or heterogeneous hyper-enhancing soft tissue mass with cystic areas on CT [2]. However, this is not specific for paragangliomas and a pancreatic neoplasm is a feasible differential.
Malignant behaviour in paragangliomas is notoriously unpredictable. Malignancy can only be definitively diagnosed with the development of metastases at sites
where paraganglionic tissue is not normally found [6]. Common sites for metastases include regional lymph nodes, liver, lung and bone. Histological features suggestive but not diagnostic of malignant behaviour include mitotic activity, vascular invasion and necrosis [7]. Malignant retroperitoneal paragangliomas are reported with an incidence of up to 50% [8]. When unresectable, paragangliomas are treated with octreotide, which may ameliorate symptoms of catecholamine excess and stabilizes tumour size [9]. Nevertheless, the pancreatic paragangliomas presented in the literature to date show a generally favourable long term outcome [5].

In summary, pancreatic paraganglioma is a very rare entity with limited cases reported. When tumours are non-secretory and the intra-pancreatic location is variable, the diagnosis of paraganglioma pre-operatively is speculative and neuroendocrine tumour is a feasible differential. Surgical resection is necessary for histological assessment. Pancreatic paragangliomas are generally benign; however, the risk of malignant transformation justifies aggressive management and any resultant post-operative morbidity.

Conflicts of interest The authors have no potential conflicts of interest

References